Evidence map›Paper›PMID 42869853›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Sphingolipid and ceramide associations with tau pathology vary across diverse ethnoracial groups in postmortem brain tissue.

Annalise Schweickart, Richa Batra, Kevin Huynh, Collette Blach, Alexandra Kueider-Paisley, Joseph S Reddy, David A Bennett, Peter J Meikle, Bin Zhang, Philip L De Jager and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Annalise SchweickartDepartment of Systems and Computational Biomedicine, Weill Cornell Medicine, New York, New York, USA.ORCID https://orcid.org/0000-0001-9691-3741
Richa BatraDepartment of Systems and Computational Biomedicine, Weill Cornell Medicine, New York, New York, USA.
Kevin HuynhBaker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Collette BlachDepartment of Psychiatry and Behavioral Sciences, Duke Institute for Brain Sciences and Department of Medicine, Duke University, Durham, North Carolina, USA.
Alexandra Kueider-PaisleyDepartment of Psychiatry and Behavioral Sciences, Duke Institute for Brain Sciences and Department of Medicine, Duke University, Durham, North Carolina, USA.
Joseph S ReddyDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
David A BennettRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.
Peter J MeikleBaker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Bin ZhangDepartment of Genetics and Genomic Sciences, Mount Sinai Center for Transformative Disease Modeling, Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Philip L De JagerCenter for Translational and Computational Neuroimmunology, Department of Neurology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.
Laura HeathSage Bionetworks, Seattle, Washington, USA.
Jaclyn BeckSage Bionetworks, Seattle, Washington, USA.
Jo ScanlanSage Bionetworks, Seattle, Washington, USA.
Nicholas T SeyfriedDepartment of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Nilüfer Ertekin-TanerDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Alzheimer's Disease Metabolomics Consortium
Rima Kaddurah-DaoukDepartment of Psychiatry and Behavioral Sciences, Duke Institute for Brain Sciences and Department of Medicine, Duke University, Durham, North Carolina, USA.
Matthias ArnoldDepartment of Psychiatry and Behavioral Sciences, Duke Institute for Brain Sciences and Department of Medicine, Duke University, Durham, North Carolina, USA.
Jan KrumsiekDepartment of Systems and Computational Biomedicine, Weill Cornell Medicine, New York, New York, USA.ORCID https://orcid.org/0000-0003-4734-3791

Funding

Project 4 - Mechanistic studies on the role of the gut microbiome in models for Alzheimer's diseaseU19AG063744 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ROB KNIGHT, Rima F Kaddurah-Daouk · 2019 to 2026
$54.1M
Peripheral and Central Biomarkers of Alzheimer's Disease in Diverse CohortsU19AG074879 · NIA · MAYO CLINIC JACKSONVILLE · PI Minerva Maria Carrasquillo · 2023 to 2026
$42.0M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2019 to 2026
$33.5M
Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's DiseaseU01AG046170 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WANG, MINGHUI, ZHANG, BIN · 2013 to 2022
$26.0M
Integrating the exposome and methylome to inform brain molecular changes in ADRD across established diverse cohorts.U01AG046139 · NIA · UNIVERSITY OF FLORIDA · PI ERTEKIN-TANER, NILUFER, FUNK, CORY · 2013 to 2022
$24.6M
Training in Basic Research on Aging and Age-Related DiseaseT32AG000266 · NIA · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Lisa M Ellerby · 1998 to 2026
$13.8M
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targetsU01AG061356 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2018 to 2022
$13.7M
Understanding the molecular mechanisms that contribute to neuropsychiatric symptoms in Alzheimer DiseaseR01AG067025 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FINKBEINER, STEVEN M, HAROUTUNIAN, VAHRAM · 2019 to 2023
$11.8M
Metabolomic Signatures for Disease Sub-classification and Target Prioritization in AMP-ADU01AG061359 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KASTENMULLER, GABI · 2018 to 2022
$10.0M
Integrative translational discovery of vascular risk factors in aging and dementiaRF1AG051504 · NIA · MAYO CLINIC JACKSONVILLE · PI BU, GUOJUN, ERTEKIN-TANER, NILUFER · 2015 to 2019
$9.8M
Supplement to AMP-AD Brain Proteomic Network Enhancement, Validation and Translation into CSF BiomarkersU01AG061357 · NIA · EMORY UNIVERSITY · PI LEVEY, ALLAN I, SEYFRIED, NICHOLAS THOMAS · 2018 to 2022
$9.1M
The Role of Chemical Exposures in Alzheimer's Disease (AD) and its TrajectoryU01AG088562 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Oliver Fiehn, LEE E. GOLDSTEIN · 2024 to 2026
$7.2M
Alzheimer's Association AARFD-22-974775Alzheimer's Association ZEN-22-969810NIA NIH HHS P30 AG062677NIA NIH HHS P30AG062677NIA NIH HHS R01 AG061796NIA NIH HHS R01AG061796NIA NIH HHS R01 AG067025NIA NIH HHS R01AG067025NIA NIH HHS R01 AG069901NIA NIH HHS R01AG069901NIA NIH HHS R01 AG081322NIA NIH HHS R01AG081322NIA NIH HHS RF1 AG051504NIA NIH HHS RFAG051504NIA NIH HHS T32 AG000266NIA NIH HHS T32AG000266NIA NIH HHS U01 AG046139NIA NIH HHS U01AG046139NIA NIH HHS U01 AG046170NIA NIH HHS U01AG046170NIA NIH HHS U01 AG061356NIA NIH HHS U01AG061356NIA NIH HHS U01 AG061357NIA NIH HHS U01AG061357NIA NIH HHS U01 AG061359NIA NIH HHS U01AG061359NIA NIH HHS U01AG061359-05S1NIA NIH HHS U01 AG088562NIA NIH HHS U01AG088562NIA NIH HHS U19 AG063744NIA NIH HHS U19AG063744NIA NIH HHS U19 AG074879NIA NIH HHS U19AG074879
6 · The paper itself

Abstract

introductionMetabolic dysregulation is a hallmark of Alzheimer's disease (AD), with numerous studies characterizing metabolic pathways associated with AD onset and progression. A limitation of these studies has been a focus on non-Hispanic white participants. Despite evidence that AD prevalence, progression, and biomarkers differ across ethnoracial groups, it remains unclear whether previously identified metabolic dysregulation in AD brains generalizes across populations.

methodsWe analyzed metabolomics data from 547 postmortem brain tissue samples of Hispanic American, Non-Hispanic African American, and White subjects, providing the largest multiethnic AD brain cohort to date. A metabolome-wide association study examined how relationships between metabolite abundance and AD neuropathology varied by ethnoracial group.

resultsForty-eight metabolites exhibited significant heterogeneity with tau pathology (Braak stage), with enrichment in tricarboxylic-acid-cycle intermediates and sphingolipid-ceramide pathway lipids, and with metabolite-tau associations driven predominantly by the Hispanic American and non-Hispanic White groups. DISCUSSION: These findings reveal ethnoracial-specific metabolic signatures of tau pathology and emphasize the need to evaluate emerging therapeutic targets across diverse groups.

Indexed as

Alzheimer DiseaseBrainCeramidesSphingolipidstau ProteinsAgedAged, 80 and overBlack or African AmericanFemaleHispanic or LatinoHumansMaleMetabolomicsWhiteCeramidesSphingolipidstau ProteinsacetylcholineAlzheimer's diseaseAMP‐AD Diverse CohortsAPOE4Braak stagebrain metabolomicsceramidedipeptidesdorsolateral prefrontal cortexethnoracial differencesLipid metabolismmetabolic heterogeneitymultiethnic cohortneurodegenerationpopulation health disparitiespost‐mortem brainprecision therapeuticssphingolipid metabolismtau pathologytricarboxylic acid cycle

Identifiers

PMID42869853
PMCPMC13661748

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.